The Cancer Foundation For The World » Ovarian Cancer

Family History Of Breast Cancer May Raise Risk For Ovarian Cancer

Jeff Daas — Sun, 02 May 2010 03:01:54 +0000

Ovarian cancer is the most deadly disease of the female reproductive system, with most cases diagnosed in later stages. Yet while ovarian cancer affects 1 in 70 women in the United States, many women have never discussed the risk with their doctor. According to Dr…
Read Full Article

Resistant Cancers ‘Opened Up’ Curcumin Nanoparticles

Jeff Daas — Fri, 30 Apr 2010 08:01:08 +0000

Pre-treatment with curcumin, a component of the spice turmeric, makes ovarian cancer cells more vulnerable to chemotherapy and radiotherapy. Researchers writing in BioMed Central’s open access Journal of Ovarian Research found that delivering the curcumin via very small (less than 100nm) nanoparticles enhanced the sensitizing effect…
Read Full Article

Ovarian Cancer Study Offers Vital Clues For New Therapies

Jeff Daas — Thu, 22 Apr 2010 23:01:46 +0000

Scientists have taken a major step forward in the understanding of ovarian cancer, which could improve treatment for patients with the condition. Researchers have found that patients with hereditary ovarian cancer – whose tumours are caused by faulty genes – are more likely to experience secondary tumours in their liver and spleen…
Read Full Article

German Study Is First To Clearly Link Mutations In The RAD51C Gene To Breast And Ovarian Cancer

Jeff Daas — Thu, 22 Apr 2010 23:01:35 +0000

The discovery 15 years ago that the genes BRCA1 and BRCA2 confer high risks for breast and ovarian cancer was a breakthrough for cancer prediction and therapy, especially for familial cases. Now the research group of Prof. Alfons Meindl (Klinikum rechts der Isar of the Technische Universitaet Muenchen), in collaboration with other groups from Germany, the U.K., and the U.S…
Read Full Article

Expression Of Proteins Linked To Poor Outcome In Women With Ovarian Cancer

Jeff Daas — Thu, 22 Apr 2010 10:01:25 +0000

Scientists have established the presence of certain proteins in ovarian cancer tissues and have linked these proteins to poor survival rates in women with advanced stages of the disease. The study, led by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health, appears in Cancer online, April 19, 2010…
Read Full Article

Spirit Of Ovarian Cancer Advocate Keeps Fundraising Drive On Track

Jeff Daas — Thu, 22 Apr 2010 10:01:18 +0000

The Anne Rita Monahan Foundation recently presented $15,000 for ovarian cancer research to the Translational Genomics Research Institute (TGen). That amount brings to $50,000 the total amount raised by the organization named for Anne Rita Monahan, a Phoenix woman who used her initials to encourage women to “ARM yourself against ovarian cancer…
Read Full Article

Drug Benefits Patients With Inherited Ovarian Cancer

Jeff Daas — Thu, 22 Apr 2010 10:01:12 +0000

A new type of cancer drug has shown promising results in patients with ovarian cancer linked to an inherited mutation, a disease for which current treatment options are limited. The trial results are published today in the Journal of Clinical Oncology…
Read Full Article

Engineered Antibodies Directed Against A Promising Therapeutic Target On Ovarian Cancer Cells

Jeff Daas — Thu, 22 Apr 2010 10:01:07 +0000

Stealthy and stubborn, ovarian cancer is a particularly vexing malignancy, difficult to diagnose in early stages and difficult to treat once it progresses further. However, research at Fox Chase Cancer Center is now focusing on one of the most promising new approaches to dealing with the disease – using engineered antibodies to target tumor cells while leaving healthy cells intact…
Read Full Article

Abstracts Highlighting Sunesis’ Phase 2 Voreloxin Data Accepted For Presentation At 2010 ASCO Meeting

Jeff Daas — Thu, 22 Apr 2010 10:00:07 +0000

Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) announced that data from three Phase 2 clinical trials of voreloxin, the company’s lead drug candidate, have been accepted for presentation at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held June 4-8 in Chicago, Illinois…
Read Full Article

Abstracts Highlighting Sunesis’ Phase 2 Voreloxin Data Accepted For Presentation At 2010 ASCO Meeting

Jeff Daas — Thu, 22 Apr 2010 09:02:12 +0000